Page 5 - Heart Failure Guidelines
P. 5

Pediatric Heart Failure Guidelines

               Chemotherapy Induced Cardiomyopathy ..................................................................................29
                  Additional Evaluation for Patient with Chemotherapy Induced Cardiomyopathy ....................29
                  Medical Management Chemotherapy Induced Cardiomyopathy ............................................29
                  Follow-up Schedule for Chemotherapy Induced Cardiomyopathy ..........................................29
               Neuromuscular Disorder Associated Cardiomyopathy ..............................................................30

                  Additional Evaluation for Patient with Neuromuscular Disorder associated Cardiomyopathy .30
               Introduction ...............................................................................................................................30
               Initial Evaluation ........................................................................................................................30
               Ongoing Management ...............................................................................................................30

                  Dose escalation plan (outpatient monitoring) .........................................................................31
               Imaging .....................................................................................................................................32
               Arrhythmia Screening ................................................................................................................32
               Advanced Therapies .................................................................................................................32
               Myocarditis ................................................................................................................................33
                  Additional Evaluation for possible Myocarditis .......................................................................33
                  Medical Management Myocarditis .........................................................................................33
                  Immunotherapy Management Myocarditis .............................................................................33
                  Follow-up Schedule for Myocarditis .......................................................................................34

               Medication Doses .....................................................................................................................35
               Anticoagulation Schedules ........................................................................................................37








































               Updated 12/4/2018                                                                       page 5
   1   2   3   4   5   6   7   8   9   10